Suggested remit: To appraise the clinical and cost effectiveness of Somapacitan within its marketing authorisation for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height
Suggested remit: To appraise the clinical and cost effectiveness of Somapacitan within its marketing authorisation for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height